Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Determination of 3-MeO-PCP in human blood and urine in a fatal intoxication case, with a specific focus on metabolites identification

Bibliographic Data

ID13119735
AuthorsNadia Arbouche (0000-0002-6676-1406, Institut de Médecine et d'Epidémiologie Africaines, corresponding author), Pascal Kintz (0000-0002-4174-5362, Institut de Médecine et d'Epidémiologie Africaines), Cecile Zagdoun, Laurie Gheddar (0000-0002-7804-3946, Institut de Médecine et d'Epidémiologie Africaines), Jean‐sébastien Raul (0000-0002-9991-3795, Institut de Médecine et d'Epidémiologie Africaines), Jean-Sébastien Raul, Alice Ameline (0000-0002-1117-0887, Institut de Médecine et d'Epidémiologie Africaines)
Year2021
Volume6
Issue3
Pages208-214
Publication date2021-06-14
Open AccessYes
TypeARTICLE
VenueForensic Sciences Research (JOURNAL)
Journal identifiersISSN: 2471-1411 • E-ISSN: 2096-1790
PublisherTaylor & Francis (PUBLISHER • GB)
DOI10.1080/20961790.2021.1928821
PMID34868712
OpenAlexW3171416805
LanguageEN
Citations received1
References cited10

3-Methoxyphencyclidine (3-MeO-PCP) is a new psychoactive substance that belongs to the phencyclidines family, first identified in Europe in 2012. This drug presents a stronger binding to N -methyl-D-aspartate (NMDA) receptors when compared to phencyclidine, which results in more potent effects, even at low concentrations. Very few articles have been published regarding 3-MeO-PCP in forensic toxicology. In this paper, the authors present a fatal 3-MeO-PCP intoxication case. In addition to the detection of the parent drug, metabolites were investigated in urine and, for the first time in the scientific literature, in blood. 3-MeO-PCP and its metabolites were quantitated by liquid chromatography-tandem mass spectrometry system (LC-MS/MS). Identification was confirmed by liquid chromatography-high resolution mass spectrometry (LC-HRMS). 3-MeO-PCP tested positive in femoral blood (3 525 ng/mL) and urine (7 384 ng/mL). The femoral blood concentration was higher than the fatal concentrations range already reported in the literature (from 50 to 3 200 ng/mL). 3-MeO-PCP metabolites, including O -demethyl-3-MeO-PCP, piperidine-OH-3-MeO-PCP, O -demethyl-piperidine-di-OH-3-MeO-PCP and piperidine-di-OH-3-MeO-PCP, were detected in blood. In addition, two new metabolites, O -demethyl-piperidine-OH-3-MeO-PCP and O -demethyl-cyclohexyl-OH, were identified in both blood and urine. Unfortunately, due to the lack of reference material on the market, it was not possible to measure the concentration of these metabolites. However, the ratios between the metabolites and the parent drug were useful to estimate their analytical response and prevalence. At this time, considering the low ratios (<1) between metabolites and parent drug, metabolites testing does not seem useful to increase the detection window of the drug

Chromatography · Designer drug · Drug · Metabolite · NMDA receptor · Phencyclidine · Piperidine · Receptor · Stereochemistry · Urine · Chemistry · Forensic Toxicology and Drug Analysis · Medicine · Neurotransmitter Receptor Influence on Behavior · Poisoning and overdose treatments · Biochemistry · Pharmacology

  • No prescription? No problem

    Open Access•Tayler Holborn, Fabrizio Schifano et al.•International Journal of Drug…•2023

Citations per year0.33
Citation span2023 - 2023 (1)
Highly citedNo

Tools

Open DOIOpen Access
Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae